Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Pediatric Blood & Cancer

• Publication date

  2007-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.20697PMID 16317751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Temozolomide in resistant or relapsed pediatric solid tumors

  2006cited by this paper
• Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma

  2004cited by this paper
• Carboplatin‐based chemotherapy for refractory and recurrent Ewing's tumours

  2004cited by this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

  2004cited by this paper
• A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.

  2003cited by this paper
• Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.

  2003cited by this paper
• Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.

  2003cited by this paper
• Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

  2003cited by this paper
• Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997.

  2003cited by this paper
• Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.

  2003cited by this paper
• Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

  2003cited by this paper
• Phase I Study of Irinotecan in Pediatric Patients With Malignant Solid Tumors

  2002cited by this paper
• High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT).

  2002cited by this paper
• CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.

  2002cited by this paper
• Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience

  2002cited by this paper
• Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.

  2001cited by this paper
• Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

  2001cited by this paper
• A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

  2001cited by this paper
• Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

  2001cited by this paper
• CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.

  2000cited by this paper
• Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

  2000cited by this paper
• Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Hochdosistherapie bei primär metastasiertem und rezidiviertem Ewing-Sarkom

  1999cited by this paper
• [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS].

  1999cited by this paper
• Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

  1999influential reference
• Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

  1998cited by this paper
• The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.

  1997cited by this paper
• Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.

  1997cited by this paper
• Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

  1996cited by this paper
• Irinotecan (CPT-11): pharmacology and clinical applications.

  1996influential reference
• Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

  1996cited by this paper
• The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation.

  1995cited by this paper

• Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study

  2025cites this paper
• Guidance for the prevention and management of adverse events in patients receiving dinutuximab beta therapy

  2025cites this paper
• Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

  2025cites this paper
• Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Revisiting Temozolomide's role in solid tumors: Old is gold?

  2024cites this paper
• The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma

  2024cites this paper
• Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response

  2024cites this paper
• Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

  2024cites this paper
• Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

  2023cites this paper
• Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.

  2023cites this paper
• Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates

  2023cites this paper
• Ewing's sarcoma family of tumors

  2022cites this paper
• The O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and clinical outcomes of Ewing sarcoma patients treated with irinotecan and temozolomide

  2022cites this paper
• Irinotecan dose schedule for the treatment of Ewing sarcoma

  2022cites this paper
• A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

  2022cites this paper
• Osteosarcoma/Ewing Sarcoma.

  2022cites this paper
• Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

  2022cites this paper
• Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

  2022cites this paper
• Challenges of Systemic Therapy Investigations for Bone Sarcomas

  2022cites this paper
• Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial

  2021cites this paper
• Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas

  2021cites this paper
• Лечение рецидивов саркомы Юинга у детей и подростков: современный взгляд

  2021cites this paper
• Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults

  2021cites this paper
• Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives

  2021cites this paper
• Chemotherapy for Pelvic Bone Tumors

  2021cites this paper
• Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study

  2021cites this paper
• Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

  2021cites this paper
• Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial

  2021cites this paper
• AN OVERVIEW OF CURRENT RESULTS WITH THE VINCRISTINE-IRINOTECAN-TEMOZOLOMIDE COMBINATION WITH OR WITHOUT BEVACIZUMAB IN PEDIATRIC, ADOLESCENCE AND ADULT SOLID TUMORS.

  2021cites this paper
• Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.

  2020cites this paper
• Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects

  2020cites this paper
• Pediatric Solid Tumors

  2020cites this paper
• Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma

  2020cites this paper
• A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas

  2020cites this paper
• Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study

  2020cites this paper
• The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?

  2020cites this paper
• Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions: Clinical, Radiological and Histological Correlations - The Rizzoli Case Archive

  2020cites this paper
• Contemporary Approach to Therapy for Ewing Sarcoma

  2020cites this paper
• High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen

  2020cites this paper
• OTT_A_193363 5093..5112

  2020cites this paper
• Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.

  2020cites this paper
• Novel prognostication of patients with spinal and pelvic chondrosarcoma using deep survival neural networks

  2020cites this paper
• Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

  2020cites this paper
• Sarcomas of Soft Tissue

  2020cites this paper
• Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults.

  2019influential citation
• Registration‐directed phase 1/2 trial of irinotecan for pediatric solid tumors

  2019cites this paper
• Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

  2019cites this paper
• Chemotherapy of Ewing Sarcoma

  2019cites this paper
• Management of recurrent Ewing sarcoma: challenges and approaches

  2019cites this paper
• Curettage, phenolization, and cementation in paediatric Ewing’s sarcoma with a complete radiological response to neoadjuvant chemotherapy

  2018cites this paper
• Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP–RTSG 2016 protocol

  2018cites this paper
• Targeting rhabdomyosarcoma with temozolomide: how autophagy regulates TMZ-induced apoptosis in rhabdomyosarcoma cells

  2018cites this paper
• Tratamiento médico de los sarcomas óseos

  2018cites this paper
• Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells

  2018cites this paper
• VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma

  2018cites this paper
• Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients

  2018influential citation
• The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

  2018cites this paper
• NCCN Guidelines Insights: Bone Cancer, Version 2.2017.

  2017cites this paper
• The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations

  2017cites this paper
• Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

  2016cites this paper
• Non-surgical Treatment of Pediatric Bone Sarcomas

  2016cites this paper
• Central nervous system recurrence of desmoplastic small round cell tumor following aggressive multimodal therapy: A case report.

  2016cites this paper
• Systemic therapy for bone sarcomas

  2016cites this paper
• Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide

  2016cites this paper
• Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: single center experience

  2016cites this paper
• UK guidelines for the management of bone sarcomas

  2016cites this paper
• Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.

  2016cites this paper
• Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

  2016cites this paper
• Management of Ewing sarcoma family of tumors: Current scenario and unmet need

  2016cites this paper
• Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

  2016cites this paper
• Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma

  2016cites this paper
• BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

  2016cites this paper
• Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor.

  2016cites this paper
• Knochen- und Weichteilsarkome des Kindes-, Jugend- und jungen Erwachsenenalters

  2016influential citation
• Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

  2016cites this paper
• Sarcomas of Soft Tissue and Bone.

  2016cites this paper
• Recurrent Bone Tumors

  2015cites this paper
• Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways

  2015cites this paper
• Irinotecan and temozolomide in adults with recurrent sarcoma

  2015cites this paper
• Chemotherapy Regimens for Patients with Newly Diagnosed Malignant Bone Tumors

  2015cites this paper
• Diagnosis and treatment of Ewing sarcoma of the bone: a review article

  2015cites this paper
• Management of Ewing Sarcoma:Current Management and the Role of Radiation Therapy

  2015cites this paper
• Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe

  2015cites this paper
• Ewing Sarcoma: Focus on Medical Management

  2015cites this paper
• The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma

  2015cites this paper
• Targeted therapies for advanced Ewing sarcoma family of tumors.

  2015cites this paper
• Etoposide and carbo‐or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study

  2015cites this paper
• Irinotecan and Temozolamide Treatment for Relapsed Ewing Sarcoma: A Single-Center Experience and Review of the Literature

  2015influential citation
• Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

  2015cites this paper
• Ewing sarcoma family of tumors

  2015cites this paper
• Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

  2014cites this paper
• A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

  2014influential citation
• A phase II window study of irinotecan (CPT‐11) in high risk ewing sarcoma: A Euro‐E.W.I.N.G. study

  2014cites this paper
• Development of Therapies for Ewing Sarcoma : Strategies for Treating a Chemosensitive Pediatric Sarcoma

  2014cites this paper
• Comparing oxazaphosphorines for treating Ewing sarcoma: is the answer important two decades later?

  2014cites this paper
• The value of high‐dose chemotherapy in patients with first relapsed Ewing sarcoma

  2014cites this paper
• Chemotherapy in Ewing Sarcoma

  2014cites this paper
• Treatment of Relapsed Wilms Tumor

  2014cites this paper
• Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors

  2014cites this paper
• Bone sarcomas : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up † The ESMO / European Sarcoma Network Working Group * incidence

  2014cites this paper